UltraSight announced a $24 million Series B2 on 23 September, led by Alive HealthTech Growth Fund. The company says the financing will support US commercial expansion and further development of its cardiac-care workflows. The amount is the announced round, not a company valuation.
Its business centres on AI guidance for acquiring cardiac ultrasound images. The commercial question extends beyond software: a hospital must establish who captures the images, who reviews them and how findings enter its existing workflow. Those are implementation questions, not claims that financing improves patient outcomes.
For Israeli health-technology investors and potential Gulf partners, the useful distinction is between funding a rollout and demonstrating its results. A prospective partner would still need to verify local permissions, training, clinical oversight and integration requirements. The financing announcement does not establish a new UAE authorisation or a Gulf distribution agreement.